Fosun Pharma announcement that the registration application for the marketing of Fuhong Hanlin and its holding subsidiary independently developed Hans-shaped (i.e. Slulizumab injection) combined with carboplatin and albumin paclitaxel for the first-line treatment of inoperable advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) has been approved by the State Food and Drug Administration.
As of the close of November 1, 2022, Fosun Pharma (600196) closed at 34.39 yuan, up 4.12%, with a turnover rate of 3.46%, a trading volume of 696,100 lots, and a trading volume of of 2.353 billion yuan. In terms of capital flow data, on November 1, the net inflow of main funds was 82.2316 million yuan, the net inflow of hot money funds was 65.7773 million yuan, and the net outflow of retail funds was 148 million yuan. In terms of margin financing and securities lending, the net outflow of financing was 50.3682 million in the past five days, and the balance of financing of decreased; the net inflow of margin financing was 334,100, and the balance of securities lending increased.
According to the financial report data in the past five years, Securities Star valuation analysis tool shows that Fosun Pharma (600196) has good competitiveness in the industry, poor profitability, and average revenue growth. Financial concerns may be hidden, and financial indicators that need to be paid attention to include: interest-bearing debt-to-asset ratio , accounts receivable/profit ratio, operating cash flow /profit ratio. The stock has a good company index of 2.5 stars, a good price index of 3 stars, and a comprehensive index of 2.5 stars. (Indicators are for reference only, indicator range: 0 ~ 5 stars, the highest 5 stars) In the past 90 days, 11 institutions in this stock have given ratings, 28 buy ratings, and 3 rated increase ratings; the average target price of institutions in the past 90 days was 59.06.
Fosun Pharma (600196) main business: pharmaceuticals, medical devices and medical diagnosis, medical health services. The company's chairman is Wu Yifang , Wang Kexin. The company's general manager is Wen Deyong.
has a heavy holding of Fosun Pharma's top ten funds , see the table below:
The fund with the largest holding is China Merchants Guozheng Biopharma Index (LOF) A, with a current scale of 13.817 billion yuan, with a latest net value of 0.5711 (October 31), down 2.19% from the previous trading day and a 36.6% drop in the past year. The current fund manager of this fund is Hou Hao and Xu Rongman.
or above content was compiled by Securities Star based on public information and has nothing to do with the position of this site. Securities Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of this information (including but not limited to text, video, audio, data and charts). If there are any problems, please contact us. This article is a data compilation and does not constitute any investment advice to you. Investment is risky, so please make prudent decisions.
